Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas

Activating mutation of BRAF is a common finding in pediatric gliomas. As many as 14% of high grade and up to 66% of certain subtypes of low grade pediatric glioma have the BRAF(V600E) mutation. Small molecule inhibitors that selectively target BRAF(V600E) are FDA approved for melanoma and have shown...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Tsun-Wen, Zhang, Jie, Prados, Michael, Weiss, William A., James, C. David, Nicolaides, Theodore
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352180/
https://www.ncbi.nlm.nih.gov/pubmed/27611946
http://dx.doi.org/10.18632/oncotarget.11882

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352180/
https://www.ncbi.nlm.nih.gov/pubmed/27611946
http://dx.doi.org/10.18632/oncotarget.11882

Ejemplares similares